1726-nm acne lasers: FDA clearance and evidence explained

A 1726-nm acne laser’s FDA clearance applies to the named prescription device and exact indication in its 510(k): long-term treatment of mild to severe inflammatory acne vulgaris. It does not clear every device using that wavelength, promise permanent clearing, authorize treatment of acne scars, or establish superiority to medication. Match the model, decision, protocol, population, endpoint, evidence window, operator, and follow-up.¹²

“The 1726 wavelength is FDA approved for acne” compresses a device decision into a category claim. The more accurate verb is cleared, and the useful unit is the exact system and intended use.

Read the 510(k) as a product record

K230660 describes a prescription infrared diode laser with a nominal 1726-nm wavelength, beam delivery, pressure sensing, and contact cooling. Its stated target is sebum in sebaceous glands, with controlled thermal injury intended to improve acne vulgaris.¹ K251149 is a later clearance for the named system with the same indication and specific device changes described in that record.²

Ask for the 510(k) number attached to the device in the room. A reseller page, wavelength sticker, establishment registration, or claim that a platform is “similar to” a cleared system is not the decision letter.

Separate active acne from acne scars

Inflammatory lesions are not the same target as ice-pick, boxcar, rolling, hypertrophic, or pigmentary changes left after acne. The clearance language names inflammatory acne vulgaris; it does not say acne-scar treatment.¹² The acne-scar guide starts with scar morphology because scar procedures act through different mechanisms.

Create separate baseline counts or descriptions for inflammatory papules and pustules, comedonal lesions, scars, redness, and pigment changes. Otherwise, a before-and-after claim may silently combine improvement in one category with persistence or change in another.

Audit the submitted protocol and the clinic protocol

The K230660 summary describes a prospective multicenter study of 104 participants aged 16 to 40 who received up to three treatments, with a 12-week primary time point and follow-up through 52 weeks. Treatment success was defined as at least a 50% reduction in inflammatory lesion count.¹ Preserve those definitions before repeating a response percentage.

Then compare the offered plan:

• exact system and handpiece;
• treatment count and spacing;
• treated anatomy and coverage pattern;
• energy, pulse and cooling framework;
• operator and prescription process;
• baseline severity and lesion-count method;
• concurrent or recently changed acne treatments;
• planned assessment dates; and
• management of flare, erythema, edema, dryness, discomfort or pigment concern.

A protocol can differ for sensible clinical reasons. The difference should be explicit rather than hidden behind the shared wavelength.

Keep 2026 evidence in its study lane

Current longer-term and real-world publications add useful observations beyond the original clearance record.⁴⁵ They do not retroactively change the 510(k) indication or erase study-design limits. Check whether a paper is prospective or retrospective, controlled or uncontrolled, which device and protocol it studied, who was lost to follow-up, how outcomes were measured, and which conflicts or manufacturer relationships were disclosed.

Use registered-study dates and outcomes to reconcile publications with the original plan.³ “Two-year data” describes an observation window; it is not the same as proof of a permanent effect in all treated people.

Build a decision-ready record

The quote should identify whether consultation, each treatment, topical products, photography, follow-up, flare management, and later maintenance are included. It should state what happens if inflammatory lesions do not change by the chosen checkpoint or if scarring is the main concern.

1. Verify the hardware. Record manufacturer, system, handpiece, serial or model, 510(k), software where relevant, and maintenance status.
2. Match the indication. Compare inflammatory-acne diagnosis, severity, anatomy, prescription status, age, and stated endpoint with the FDA record.
3. Reconcile protocols. Place the submitted study schedule and settings framework beside the clinic's proposed plan and explain material differences.
4. Choose separate measures. Track inflammatory lesions, other lesion types, scars, pigment, symptoms and photographs without blending them into one score.
5. Assign follow-up. Name expected reactions, contact paths, assessment dates, other acne-care coordination, and the alternative plan if the target is not met.

The decisive question is: “Does this exact cleared device, protocol, population, and inflammatory-acne endpoint match the service being sold?”